Emergency care in a sudden individually significant blood pressure increase without clinically overt target organ damage: rationale for captopril use. Expert Council opinion
Open Access
- 11 March 2020
- journal article
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 25 (2), 103-110
- https://doi.org/10.15829/1560-4071-2020-2-3748
Abstract
Expert Council opinion describes emergency care in a sudden individually significant blood pressure (BP) increase without clinically overt target organ damage. In the new guidelines of the Russian Society of Cardiology, the term “hypertensive urgency” was abolished, and the management of a sudden BP increase was changed. At the same time, a sudden individually significant BP increase may be accompanied by symptoms that reduce patients’ quality of life and ability to work. According to experts, individually significant BP increase accompanied by symptoms requires outpatient treatment using oral rapid-onset drugs with an optimal duration of action, in particular captopril. It has a much evidence-based data on the BP increase use and sublingual administration, and also has a favorable safety profile, which allows prescribing to patients with comorbid diseases. The rationale for the use of angiotensin-converting enzyme inhibitor Capoten (captopril) as a drug for self-management of a sudden individually significant BP increase accompanied by symptoms in hypertension patients is describes.Keywords
This publication has 20 references indexed in Scilit:
- Cardiorenal End Points in a Trial of Aliskiren for Type 2 DiabetesThe New England Journal of Medicine, 2012
- Hypertensive Urgencies in the Emergency Department: Evaluating Blood Pressure Response to Rest and to Antihypertensive Drugs With Different ProfilesThe Journal of Clinical Hypertension, 2008
- Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular EventsThe New England Journal of Medicine, 2008
- Treatment of Acute Severe HypertensionDrugs, 2008
- A comparison of safety and efficacy of sublingual captopril with sublingual nifedipine in hypertensive crisisInternational Journal of Angiology, 1999
- A pharmacokinetic and pharmacodynamic evaluation of buffered sublingual captopril in patients with congestive heart failureEuropean Journal of Clinical Pharmacology, 1996
- The effect of pH on the buccal and sublingual absorption of captoprilEuropean Journal of Clinical Pharmacology, 1995
- Sublingual captopril ? a pharmacokinetic and pharmacodynamic evaluationEuropean Journal of Clinical Pharmacology, 1991
- NEGLIGIBLE SUBLINGUAL ABSORPTION OF NIFEDIPINEThe Lancet, 1987
- SUBLINGUAL CAPTOPRIL IN HYPERTENSIVE CRISISThe Lancet, 1985